Company Statements

The information contained in company statements should be considered accurate only as of the date of the company statement. We disclaim any obligation to supplement or update the information in these company statements.

Incyte Expands its Support for People Living with Vitiligo Launching Vitiligo Innovators Program™ in Conjunction with Incyte Ingenuity Awards in Vitiligo™

June 22, 2024

2023 Incyte Ingenuity Awards in Graft-Versus-Host Disease Awarded to Vanderbilt University and Massachusetts General Hospital Institute of Health Professions

November 1, 2023

Incyte Announces Inaugural Incyte Ingenuity Award Program Recipients, Recognizing Innovative Solutions for the Vitiligo Community

June 25, 2023

Cincinnati Children’s Hospital Medical Center and Children’s Healthcare of Atlanta Receive 2022 Incyte Ingenuity Awards in Graft-Versus-Host Disease

November 1, 2022

Incyte Recognized as an Exceptional Workplace by both Science Magazine and Newsweek

October 27, 2022

Incyte Pledges Support to Vitiligo Community through Expansion of Ingenuity Award Program

June 25, 2022

Incyte Announces European Commission Approval of Tabrecta® (capmatinib) for METex14 Skipping Advanced Non-Small Cell Lung Cancer

June 22, 2022

Incyte Reaffirms Commitment to Delaware Community by Opening New Research Facility and Extending the Incyte Cancer Care Assistance Fund for Delaware

April 4, 2022

Corporate Statement Regarding Opzelura™ (ruxolitinib) Cream

November 2, 2021

Incyte Announces 2021 Incyte Ingenuity Award Program Recipients, Recognizing Innovative Solutions for the GVHD Community

October 29, 2021

Incyte Ranked Second Among Science Magazine’s 2021 Top Biopharma Employers

October 28, 2021

Incyte Named to Newsweek’s List of America’s Most Loved Workplaces for 2021

October 22, 2021

Incyte Announces Progress on Global Responsibility Initiatives and Sets Corporate Goals for the Next Four Years

July 28, 2021

Incyte Statement Regarding U.S. Department of Justice Settlement

May 4, 2021

Annual Call for Submissions Open for the Incyte Ingenuity Award Program

February 24, 2021

Incyte Joins the Myeloproliferative Neoplasm (MPN) Community in Recognizing MPN Awareness Day and the 10th Anniversary of Blood Cancer Awareness Month

September 1, 2020

Data from Investigator Initiated Study of Ruxolitinib in Patients with Severe COVID-19 Published in the Journal of Allergy and Clinical Immunology

May 26, 2020

Incyte Provides Statement on NIH Initiated Trial of Baricitinib in Combination with Remdesivir for Patients with COVID-19

May 8, 2020

Incyte Provides Updated Statement on Response to COVID-19

March 30, 2020

Incyte Named a Top Five Biopharma Employer by Science Magazine

October 24, 2019

Incyte Supports Wilmington Friends School Strategic Vision and Plan for the Future

October 10, 2019

Incyte Provides Statement on World Health Organization Global Medical Product Alert for Iclusig® (ponatinib)

May 3, 2019

Incyte Provides Statement on Incyte Corporation versus Flexus Biosciences, Inc. Verdict

November 8, 2018